Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
O-I Glass | OI | Nov 22, 2024 | 12.93 | +0.62 |
Oak Valley Bancorp | OVLY | Nov 22, 2024 | 30.71 | +1.79 |
Oak Woods Acquisition | OAKU | Nov 22, 2024 | 11.36 | 0.00 |
Oaktree Acquisition III Life Sciences Unit | OACCU | Nov 22, 2024 | 10.22 | 0.00 |
Oaktree Capital A Pref | OAK-A | Nov 22, 2024 | 23.56 | -0.38 |
Oaktree Capital Group B Pref | OAK-B | Nov 22, 2024 | 22.65 | +0.18 |
Oaktree Specialty | OCSL | Nov 22, 2024 | 15.85 | +1.86 |
Oatly ADR | OTLY | Nov 22, 2024 | 0.73 | +3.38 |
Oblong | OBLG | Nov 22, 2024 | 3.39 | +3.04 |
Occidental Petroleum | OXY | Nov 22, 2024 | 51.93 | +0.76 |
Ocean Biomedical | OCEA | Nov 22, 2024 | 0.72 | +1.00 |
Ocean Power Technologies | OPTT | Nov 22, 2024 | 0.16 | +1.10 |
Oceaneering International | OII | Nov 22, 2024 | 30.03 | +4.23 |
OceanFirst Financial | OCFC | Nov 22, 2024 | 20.88 | +3.67 |
OceanFirst Pref | OCFCP | Nov 22, 2024 | 25.20 | -0.20 |
OceanPal | OP | Nov 22, 2024 | 1.44 | -1.37 |
Ocugen | OCGN | Nov 22, 2024 | 0.91 | +0.72 |
Ocular Therapeutix | OCUL | Nov 22, 2024 | 8.83 | +3.64 |
Oculis | OCS | Nov 22, 2024 | 14.76 | +0.07 |
Ocuphire Pharma | OCUP | Nov 22, 2024 | 1.17 | 0.00 |
Oddity Tech | ODD | Nov 22, 2024 | 45.56 | +5.66 |
Odyssey Marine Exploration | OMEX | Nov 22, 2024 | 0.39 | -0.15 |
Offerpad Solutions A | OPAD | Nov 22, 2024 | 4.08 | +6.53 |
Office Properties | OPI | Nov 22, 2024 | 1.14 | 0.00 |
OFG Bancorp | OFG | Nov 22, 2024 | 45.52 | +2.50 |
OFS Capital | OFS | Nov 22, 2024 | 8.15 | +1.37 |
OFS Credit | OCCI | Nov 22, 2024 | 7.11 | +0.57 |
OFS Credit C Pref | OCCIO | Nov 22, 2024 | 24.66 | -0.34 |
OFS Credit Company Pref F | OCCIM | Nov 22, 2024 | 24.93 | 0.00 |
OFS Credit E Pref | OCCIN | Nov 22, 2024 | 23.85 | -0.63 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.